Fair Pricing of Innovative Medicines: An EHA Position Paper.
作者信息
Hagenbeek Anton, Gribben John, Jäger Ulrich, Kapitein Peter, Merlini Giampaolo, Piggin Maria, Groot Carin A Uyl-de, Doeswijk Robin
机构信息
Department of Hematology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Barts Cancer Institute, Queen Mary University of London, London, UK.
出版信息
Hemasphere. 2020 Sep 30;4(5):e488. doi: 10.1097/HS9.0000000000000488. eCollection 2020 Oct.
Abstract
摘要
相似文献
1
Fair Pricing of Innovative Medicines: An EHA Position Paper.创新药物的公平定价：欧洲血液学协会立场文件
Hemasphere. 2020 Sep 30;4(5):e488. doi: 10.1097/HS9.0000000000000488. eCollection 2020 Oct.
2
Affordability of Medicines a Top Priority for EHA: Toward a Fair Pricing Model for Innovative Medicines.药品可负担性是欧洲血液学协会的首要任务：迈向创新药物的公平定价模式。
Hemasphere. 2017 Dec 20;1(1):e12. doi: 10.1097/HS9.0000000000000012. eCollection 2017 Dec.
3
[Risk sharing methods in middle income countries].[中等收入国家的风险分担方法]
Acta Pharm Hung. 2012;82(1):43-52.
4
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications.欧洲癌症药物定价的潜在方法，以提高医疗保健系统的可持续性及其影响。
Expert Rev Pharmacoecon Outcomes Res. 2021 Aug;21(4):527-540. doi: 10.1080/14737167.2021.1884546. Epub 2021 Mar 11.
5
A Framework for the Fair Pricing of Medicines.药品合理定价框架
Pharmacoeconomics. 2024 Feb;42(2):145-164. doi: 10.1007/s40273-023-01325-z. Epub 2023 Dec 8.
6
Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis.阿尔及利亚、摩洛哥和突尼斯的药品定价与报销政策：比较分析
J Mark Access Health Policy. 2023 Aug 20;11(1):2244304. doi: 10.1080/20016689.2023.2244304. eCollection 2023.
7
New pricing models for generic medicines to ensure long-term sustainable competition in Europe.确保欧洲长期可持续竞争的仿制药新定价模式。
Front Pharmacol. 2023 Oct 9;14:1200641. doi: 10.3389/fphar.2023.1200641. eCollection 2023.
8
Tackling reimbursement challenges to fair access to medicines - introduction to the topic.解决公平获得药物的报销挑战 - 主题介绍。
Expert Rev Pharmacoecon Outcomes Res. 2023 Jul-Dec;23(6):597-606. doi: 10.1080/14737167.2023.2203384. Epub 2023 Apr 17.
9
Access to Affordable Orphan Medicines in Europe: An EHA Position Paper.欧洲可负担得起的孤儿药获取：一份欧洲血液学协会立场文件。
Hemasphere. 2020 Sep 30;4(5):e477. doi: 10.1097/HS9.0000000000000477. eCollection 2020 Oct.
10
Recent Pricing Negotiations on Innovative Medicines Pilot in China: Experiences, Implications, and Suggestions.中国创新药价格谈判试点的近期情况：经验、启示与建议
Value Health Reg Issues. 2018 May;15:133-137. doi: 10.1016/j.vhri.2018.01.009. Epub 2018 May 3.
引用本文的文献
1
Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review.关于潜在创新型卫生技术的价格决定因素及定价政策：一项范围综述
Eur J Health Econ. 2025 Sep 6. doi: 10.1007/s10198-025-01834-y.
2
Valuation of Medical Innovation Handling with Uncertainty and Risk.医疗创新的估值：应对不确定性与风险
J Mark Access Health Policy. 2024 Aug 1;12(3):199-208. doi: 10.3390/jmahp12030016. eCollection 2024 Sep.
3
Towards ethical drug pricing: the European Orphan Genomic Therapies Fund.迈向伦理药物定价：欧洲孤儿基因组治疗基金。
Gene Ther. 2024 Jul;31(7-8):353-357. doi: 10.1038/s41434-024-00452-2. Epub 2024 Apr 24.
4
How to balance valuable innovation with affordable access to medicines in Belgium?如何在比利时平衡有价值的创新与民众负担得起的药品可及性？
Front Pharmacol. 2022 Sep 16;13:960701. doi: 10.3389/fphar.2022.960701. eCollection 2022.
5
Value-based pricing for advanced therapy medicinal products: emerging affordability solutions.基于价值的先进治疗药物定价：新兴的负担能力解决方案。
Eur J Health Econ. 2022 Mar;23(2):155-163. doi: 10.1007/s10198-021-01276-2. Epub 2021 Jun 9.
6
Access to Affordable Orphan Medicines in Europe: An EHA Position Paper.欧洲可负担得起的孤儿药获取：一份欧洲血液学协会立场文件。
Hemasphere. 2020 Sep 30;4(5):e477. doi: 10.1097/HS9.0000000000000477. eCollection 2020 Oct.
本文引用的文献
1
Access to Affordable Orphan Medicines in Europe: An EHA Position Paper.欧洲可负担得起的孤儿药获取：一份欧洲血液学协会立场文件。
Hemasphere. 2020 Sep 30;4(5):e477. doi: 10.1097/HS9.0000000000000477. eCollection 2020 Oct.
2
Here to Stay: Biosimilars in Hematology.常驻于此：血液学中的生物类似药
Hemasphere. 2019 Nov 19;3(6):e323. doi: 10.1097/HS9.0000000000000323. eCollection 2019 Dec.
3
Biologicals and Biosimilars in Hematology: The Case of Rituximab.血液学中的生物制品和生物类似药：利妥昔单抗的案例
Hemasphere. 2019 Nov 19;3(6):e322. doi: 10.1097/HS9.0000000000000322. eCollection 2019 Dec.
4
Affordability of Medicines a Top Priority for EHA: Toward a Fair Pricing Model for Innovative Medicines.药品可负担性是欧洲血液学协会的首要任务：迈向创新药物的公平定价模式。
Hemasphere. 2017 Dec 20;1(1):e12. doi: 10.1097/HS9.0000000000000012. eCollection 2017 Dec.
5
A proposal for value informed, affordable ("via") prices for innovative medicines.关于创新药物价值导向型可承受价格（“VIA”价格）的提议。
J Med Econ. 2019 Nov;22(11):1235-1239. doi: 10.1080/13696998.2019.1632203. Epub 2019 Jul 8.
6
Sustainability and affordability of cancer drugs: a novel pricing model.癌症药物的可持续性与可负担性：一种新型定价模式
Nat Rev Clin Oncol. 2018 Jul;15(7):405-406. doi: 10.1038/s41571-018-0027-x.
7
Costs of haematological disease high and rising.血液疾病的成本高昂且不断攀升。
Lancet Haematol. 2016 Aug;3(8):e353-4. doi: 10.1016/S2352-3026(16)30074-6. Epub 2016 Jul 22.
Zotero 插件